CFDE Data Portal | Search LOC339298

	Label	Description
	LOC339298 associations Collection (Entity type)	Associations for LOC339298_associations
	LOC339298 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	LOC339298 Gene (Entity type)	ENSG00000263547 - uncharacterized LOC339298
	GSE119424 GSE120214 TBXT brachyury inhibition 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE179235 MEK NRAS inhibition 4 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 9 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Pituitary 20-29 vs 70-79 Down Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Pituitary 20-29 vs 50-59 Down Gene Set (Entity type)	A Gene Set from GTEx
	GSE206959 reserpine 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC339298 associations

Associations for LOC339298_associations

LOC339298 associations.tsv

A file from IDG as part of the Harmonizome project

LOC339298

ENSG00000263547 - uncharacterized LOC339298

GSE119424 GSE120214 TBXT brachyury inhibition 1 v 3 human up

A Gene Set from LINCS

GSE195568 palbociclib 2 v 4 human up

A Gene Set from LINCS

GSE179235 MEK NRAS inhibition 4 v 3 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 9 v 7 human dn

A Gene Set from LINCS

GTEx Pituitary 20-29 vs 70-79 Down

A Gene Set from GTEx

GTEx Pituitary 20-29 vs 50-59 Down

A Gene Set from GTEx

GSE206959 reserpine 2 v 3 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.